Agency Edition · the primary path
Before pharma buys this directly, control your engine.
The pharma DTC content production layer is being eaten by AI on a 12-month horizon. Independent agencies that move first — license the OVYN engine (Intelligence + Content Engine + Activation), white-label, keep client relationships — keep their scope. Agencies that wait, lose it. This is the conversation we should be having.
For PE-backed + boutique pharma agencies
You can license the engine. Or compete with it.
Pharma DTC content production — variant adaptation, MLR prep, channel formatting, performance reporting — is the agency layer most exposed to AI displacement on a 12-month horizon. We built the engine that does it. Your move is to license it under your brand, keep client relationships, and let your strategy team focus on the work that's actually defensible: positioning, brand voice, account leadership.
The window
~12 mo
Before pharma starts buying this directly. Movers eat the market.
The argument
Why agencies move now, not next year.
01
65–70% of your current scope is being eaten by AI in 12 months
Independent industry analysis: pharma DTC creative production — variant adaptation, MLR prep, channel formatting, performance reporting — is the layer most exposed to AI displacement. The strategic + creative-direction work survives. The production layer doesn't.
02
Your client is going to ask if you have an AI answer
If you don't, they'll go direct to platforms like this one. If you do — they stay with you. The question for agency leadership is whether you're licensing the engine or competing with it on day one.
03
Big agencies are still building. Boutiques are not.
Publicis Health, Real Chemistry, Indegene have been talking about AI content for two years and still aren't shipping at scale internally. Boutique and PE-backed independents don't have the budget to wait. Licensing is the fastest path to AI-enabled.
What you get
The agency edition.
- White-label the entire platform under your brand and domain
- Your account team drives the brief generator + version production
- Your client never sees OVYN — they see your engine
- Per-seat license + revenue share on closed pharma deals you bring
- Co-branded option also available if you'd rather acknowledge the underlying engine
- 2-week reskin (your colors, fonts, lockup, domain) · 4-6 week full embed
- Per-client exclusivity — we don't take a parallel direct engagement with any client you bring
Where we won't undercut you
The boundary.
- We don't sell direct to your clients while you're under contract
- We don't replace your strategy + creative-direction work — those stay yours
- We don't take you down a vendor-procurement path — you license, integrate, and resell
- We don't restrict your existing tools — Veeva, your CRM, your DSP, your reporting all stay
The economics
License + revenue share. Both sides win when you bring deals.
Per-seat license
$24K / seat / yr
3-seat minimum · unlimited version generation · unlimited brands · platform updates included
Year-1 revenue share
30%
Of first-year ACV on every pharma deal you source. Paid quarterly.
Lifetime tail
15%+
Revenue share continues lifetime on the relationship · 20% in years 2-3, 15% thereafter
Math example: One PE-backed agency licensing 5 seats ($120K) brings 4 pharma clients ($350K avg ACV each = $1.4M total). Year-1 revenue share to agency = $420K. Net agency receives = $300K to take to the table, plus retains the $1.4M client relationships. We make $980K + the seat license. Both sides ahead of where they would be alone.
Agency leadership FAQ
The questions you'd ask before signing.
What does white-label cost?
Per-seat license starting at $24K per seat per year, with a 3-seat minimum (so $72K minimum annual). On top: revenue share on pharma deals you close — 30% of first-year ACV, 20% in years 2–3, 15% lifetime thereafter. We're flexible on structure — flat license vs revenue-share weighted is a conversation.
How fast can you reskin?
2 weeks for a full reskin: your brand colors, fonts, domain, lockup, favicon, OG image. 4–6 weeks for a full embed into your existing client portal if that's the goal. We've architected for white-label from day one — the entire palette is in a single config file.
Do you take agencies exclusive in a vertical?
Per-client exclusive: yes. If you bring us a pharma client, we don't take a parallel direct engagement with that client during your contract term. Globally non-exclusive across categories — multiple agencies can license simultaneously. We do prefer one deeply-embedded media-agency partner per biotech-vertical though, so let us know early.
What if my client wants to deal direct with you?
Standard agency-side language in the contract: any deal sourced through your relationships pays you the revenue share regardless of how the contract is structured. We don't end-run partners. If a client insists on direct, we negotiate a transition or step-down.
Will my account team have to learn a new platform?
Yes, but they're trained, not expected to figure it out. 2-week onboarding workshop with your strategy + AD team. After that, the team operates the engine for your clients exactly the same way they'd run a creative brief through your existing process — just faster.
What about my existing client SOWs?
We integrate underneath your existing scope. Your SOW with the client doesn't change. Your account team uses the engine on the production layer; from the client's view, you've just gotten faster + more variant-rich. The internal cost change is yours to manage.
Other partnership paths
If you're not an agency · three other ways to plug in.
Media buying agencies + ad-tech operatorsChannel partner · media side
You buy paid media for biotech clients. We integrate at the file-handoff point — MLR-approved creative flows from us into your portal, performance flows back via API into our dashboard. Your client sees one unified view.
Structure: Direct API integration at no cost · referral fee on warm intros · joint pitches to mutual prospects
Ex-pharma marketing leaders + senior consultantsOperator partner
You've sat on the brand side. You know which deals are real, which procurement teams move fast, which biotechs are AI-curious right now. You bring warm intros; we close + deliver.
Structure: Generous referral economics on closed deals · advisor equity option for repeat senders · co-pitch role if you want it
Adjacent SaaS + AI tools serving pharmaTechnology partner
You sell into pharma marketing in an adjacent category — analytics, MLR workflow, audience data, asset management. We integrate so customers see seamless value across both stacks. No redundancy, no overlap.
Structure: Joint integration roadmap · co-marketing on shared accounts · standard data exchange APIs
Have a deal in mind · or want to license?
Subject: who you are, agency name, what your typical client base looks like. We respond fast on real conversations.
Forward thisOne click to the right page for whoever you need to loop in.
What's underneathArchitecture · advisors · published thinking.
Talk to us30 minutes with Maha + Zein. No deck, no sales motion. We answer your questions.
About Ephicacy Health
We’re building something different.
Ephicacy Healthcare Communications is where the precision of science, the art of storytelling, and intelligent operations converge to reshape healthcare communications — across medical communications, creative advertising, and public relations. OVYN™ is the platform that delivers that work at modern speed.
Let’s Collaborate →Five expertise pillars
- Strategic Leadership
- Medical Communications
- Creative Advertising
- Public Relations
- Customer Experience
- Data-Driven Imagination
136
Years collective experience